Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

Fig. 3

Proportion of patients in the T2T study maintaining remission or LDA in period 2, according to response category in period 1 for the remission criteria of DAS28 (a), ACR/EULAR Boolean (b), and CDAI (c). ACR American College of Rheumatology, CDAI Clinical Disease Activity Index, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, DAS28 Disease Activity Score in 28 joints, ETN50 etanercept 50 mg, EULAR European League Against Rheumatism, LDA low disease activity, MTX methotrexate, PBO placebo

Back to article page